Potential Hazard of Serotonin Syndrome Associated With Dexfenfluramine Hydrochloride (Redux)

JAMA: The Journal of the American Medical Association

Volumn 276, Issue 15, 1996, Pages 1220-

  Schenck, Carlos H ^a   Mahowald, Mark W ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DEXFENFLURAMINE; LITHIUM CARBONATE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNITED STATES;

EID: 0029834326     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1996.03540150022019     Document Type: Letter

References (5)

1. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2:1142-1145.
2. O'Connor HT, Richman RM, Steinbeck KS, Caterson ID. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow-up. Int J Obes Relat Metab Disord. 1995;19:181-189.
3. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology. 1995;45:219-223.
4. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology, and management. Drug Saf. 1995;13:94-104.
5. McTavish K, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs. 1992;43:713-733.